{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79","value":"12.1"},{"groupId":"OG001","spread":"8.52","value":"13.3"},{"groupId":"OG002","spread":"7.37","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Cmax: MAAA-1181a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.81","value":"9.08"},{"groupId":"OG001","spread":"1.86","value":"7.62"},{"groupId":"OG002","spread":"3.75","value":"9.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cmax: MAAA-1181a, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.294","value":"0.316"},{"groupId":"OG001","spread":"0.237","value":"0.290"},{"groupId":"OG002","spread":"2.28","value":"0.772"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Ctrough: MAAA-1181a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.19","value":"0.714"},{"groupId":"OG001","spread":"0.138","value":"0.378"},{"groupId":"OG002","spread":"1.95","value":"1.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Ctrough: MAAA-1181a Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for MAAA-1181a were estimated in each participant using standard noncompartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG001","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG002","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)","title":"Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of MAAA-1181 Following Treatment With DS-8201a","type":"SECONDARY","unitOfMeasure":"ng/mL"}